Captopril (Capoten®,E.R. Squibb & Sons)

Atkinson AB Robertson JIS. Captopril in the treatment of clinical hypertension and cardiac failure. Lancet 1979; 2: 836–9.

Heel RC Brogden RN Speight TM Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 1980; 20: 409–52.

Case DB Atlas SA Laragh JA Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients. Prog Cardiovasc Dis 1978; 27: 195–206.

Gavras H Brunner HR Turini G Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14255 in man. N Engl J Med 1978; 298: 991–5.

Brunner HR Gavras H Waeber B Oral angiotension-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med 1979; 90: 19–23.

Johnston CI McGrath BP Millar JA Matthews PG. Long-term effects of captopril (SQ 14,225) on blood pressure and hormone levels in essential hypertension. Lancet 1979; 2: 493–6.

Atlas SA Case DB Sealey JE Laragh JH McKinstry DN. Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension 1979; 1: 274–80.

Atkinson AB Morton JJ Brown JJ Captopril in clinical hypertension. Br Heart J 1980; 44: 290–6.

Maruyama A Ogihara T Naka T Long-term effects of captopril in hypertension. Clin Pharmacol Ther 1980; 28: 316–23.

Karlberg BE Ohman KP Nilsson OR Wettre S. Captopril lowers urinary kallikrein in hypertensive patients. Lancet 1980; 1: 150–1.

Aberg HE Frithz G Morlin C. The effect of captopril on the serum level of prolactin. IRCS Med Sci 1980; 8: 217.

Warren SE O'Connor DT. Hyperkalemia resulting from captopril administration. JAMA 1980; 244: 2551–2.

Fagard R Amery A Reybrouck T Lijnen P Billiet L. Acute and chronic systemic and pulmonary hemodynamic effects of angiotensin converting enzyme inhibition with captopril in hypertensive patients. Am J Cardiol 1980; 46: 295–300.

Mullane KM Moncada S. Prostacylin mediates the potentiated hypertensive effect of bradykinin following captopril therapy. Eur J Pharmacol 1980; 66: 355–65.

Hornyck A Safar M Gitelman R The effect of captopril (C) on plasma and urinary prostaglandins (PG) in essential hypertension. London: World conference on clinical pharmacology and therapeutics, abstract 0410, 1980: 3–9 (per 2).

Crantz FR Swartz SL Hollenberg NK Role of prostaglandins in the hypotensive response to captopril in essential hypertension. Clin Res 1979; 27: 592A.

Swartz SL Williams GH Hollenberg NK Captopril-induced changes in prostaglandin production. J Clin Invest 1980; 65: 1257–64.

Abe K Itoh T Satoh M Indomethacin (IND) inhibits an enhanced renin release following the captopril, SQ 14225, administration. Life Sci 1980; 26: 561–5.

Provoost AP. The effect of prostaglandin synthesis inhibition of the acute blood pressure reduction by captopril in pentobarbital-anaesthetized rats. Eur J Pharmacol 1980; 65: 425–8.

Kripalani KJ McKinstry DN Singhvi SM Disposition of captopril in normal subjects. Clin Pharmacol Ther 1980; 27: 636–41.

Devlin RG Fleiss PM. Selective resistance to the passage of captopril into human milk. Clin Pharmacol Ther 1980; 27: 250.

Rommel AJ Pierides AM Heald A. Captopril elimination in chronic renal failure. Clin Pharmacol Ther 1980; 27: 282.

Ferguson RK Vlasses PH Koplin JR Captopril in severe treatment-resistant hypertension. Am Heart J 1980; 99: 579–85.

McKinstry DN Kripalani KJ Migdalof BH Willard DA. The effect of repeated administration of captopril (CP) on its disposition in hypertensive patients. Clin Pharmacol Ther 1980; 27: 270.

White NJ Yahaya H Rajagopalan B Ledingham JGG. Captopril and frusemide in severe drug-resistant hypertension. Lancet 1980; 2: 108–10.

Atkinson AB Lever AF Brown JJ Robertson JIS. Combined treatment of severe intractable hypertension with captopril and diuretic. Lancet 1980; 2: 105–8.

Atkinson AB Brown JJ Lever AF Captopril or frusemide in drug-resistant hypertension? (letter). Lancet 1980; 2: 699–700.

Aurell M Rudin A Tisell LE Captopril effect on hypertension in patient with renin-producing tumour. Lancet 1979; 2: 149–50.

Lopez-Ovejero JA Saal SD D'Angelo WA Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N Engl J Med 1979; 300: 1417–9.

Sharpe DN. Comparison of captopril (SQ 14225) with hydrochlorothiazide in the treatment of mild and moderate essential hypertension. Med J Aust 1979; 2: 24–6.

McNeil JJ Anderson A Christophidis W Comparison of captopril and hydrochlorothiazide in the treatment of moderate hypertension. Med J Aust 1979; 2: 22–4.

Whitworth JA Walter NMA Kincaid-Smith P. Clinical trial of an orally administered converting enzyme inhibitor (captopril). Med J Aust 1979; 2: 27–30.

Staessen J Fagard R Lijnen P Verschueren LJ Amery A. Beta blockade during captopril treatment for hypertension. N Engl J Med 1980; 303: 1121.

MacGregor GA Markandu ND Roulston JE Jones JC. Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme. Br Med J 1979; 2: 1106–9.

Zawada ET Stinson J Ramirez G. Hypertension screening and treatment with angiotensin inhibitor. Postgrad Med 1980; 68: 89–96.

Man In'T Veld AJ Wenting GJ Schalekamp MADH . Does captopril lower blood pressure in anephric patients? Br Med J 1979, 2: 1110.

Leslie BR Case DB Sullivan JF Vaughan ED Jr. Absence of blood-pressure lowering effect of captopril in anephric patients. Br Med J 1980; 280: 1067–8.

Turini GA Gribic M Brunner HR Improvement of chronic congestive heart-failure by oral captopril. Lancet 1979; 1: 1213–5.

Sharpe DN Coxon RJ Douglas JE Long B. Low-dose captopril in chronic heart failure: acute haemodynamic effects and long-term treatment. Lancet 1980; 2: 1154–7.

Dzau VJ Colucci WS Williams GH Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. N Engl J Med 1980; 302: 1173–9.

Takeda R Morimoto S Uchida K Effects of captopril on both hypertension and proteinuria. Arch Intern Med 1980; 140: 1531–3.

Oberfield SE Case DB Levine LS Use of the oral angiotensin I-converting enzyme inhibitor (captopril) in childhood malignant hypertension. J Pediatr 1979; 95: 641–4.

Friedman A Chesney RW Ball D Goodfriend T. Effective use of captopril (angiotensin I-converting enzyme inhibitor) in severe childhood hypertension. J Pediatr 1980; 97: 664–7.

Captopril: product monograph. E.R. Squibb & Sons, Inc. April, 1981.

Gavras I Graff LG Rose BD Fatal pancytopenia associated with the use of captopril. Ann Intern Med 1981; 94: 58–9.

Case DB Atlas SA Mouradian JA Proteinuria during long-term captopril therapy. JAMA 1980; 244: 346–9.

Hoorntje SJ Donker AJM Prins EJL Weening JJ. Membranous glomerulopathy in a patient on captopril. Acta Med Scand 1980; 208: 325–9.

Rosendorff C Milne FJ Levy H Nephrotic syndrome during captopril therapy. SA Med J 1980; 58: 172–3.

Bailey RR. Malignant hypertension developing while on captopril. NZ Med J 1980; 92: 31.

Collste P Haglund K Lundgren G Reversible renal failure during treatment with captopril. Br Med J 1979; 2: 612–3.

Atkinson AB Brown JJ Leckie B Captopril in a hyponatremic hypertensive: need for caution in initiating therapy. Lancet 1979; 1: 557–8.

Baker KM Johns DW Ayers CR Carey RM. Ischemic cardiovascular complications concurrent with administration of captopril: a clinical note. Hypertension 1980; 2: 73–4.

Pipkin FB Turner SR Symonds EM. Possible risk with captopril in pregnancy: some animal data. Lancet 1980; 1: 1256.

Warren SE. False-positive urine ketone test with captopril. N Engl J Med 1980; 303: 1003–4.

Waeber B Brunner HR Brunner DB Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension 1980; 2: 236–42.